A prospective study of atopic dermatitis managed without topical corticosteroids for a 6-month period
- PMID: 27445501
- PMCID: PMC4938118
- DOI: 10.2147/CCID.S109946
A prospective study of atopic dermatitis managed without topical corticosteroids for a 6-month period
Abstract
Topical corticosteroids (TCS) are regarded as the mainstay treatment for atopic dermatitis (AD). As AD has a tendency to heal naturally, the long-term efficacy of TCS in AD management should be compared with the outcomes seen in patients with AD not using TCS. However, there are few long-term studies that consider patients with AD not using TCS. We designed a prospective multicenter cohort study to assess the clinical outcomes in patients with AD who did not use TCS for 6 months and then compared our results with an earlier study by Furue et al which considered AD patients using TCS over 6 months. Our patients' clinical improvement was comparable with the patients described in Furue's research. In light of this, it is reasonable for physicians to manage AD patients who decline TCS, as the expected long-term prognosis is similar whether they use TCS or not.
Keywords: atopic dermatitis; topical corticosteroids; topical steroid addiction.
Figures


Similar articles
-
Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis.Am J Clin Dermatol. 2022 Jul;23(4):547-559. doi: 10.1007/s40257-022-00702-2. Epub 2022 Jul 20. Am J Clin Dermatol. 2022. PMID: 35857179 Free PMC article. Clinical Trial.
-
Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4).Br J Dermatol. 2022 Sep;187(3):338-352. doi: 10.1111/bjd.21630. Epub 2022 Jul 20. Br J Dermatol. 2022. PMID: 35484697 Clinical Trial.
-
Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results.J Allergy Clin Immunol. 2022 Mar;149(3):977-987.e14. doi: 10.1016/j.jaci.2021.07.036. Epub 2021 Aug 14. J Allergy Clin Immunol. 2022. PMID: 34403658 Clinical Trial.
-
A Comparison of Topical Corticosteroids and Topical Calcineurin Inhibitors for the Treatment of Atopic Dermatitis.J Allergy Clin Immunol Pract. 2023 May;11(5):1347-1359. doi: 10.1016/j.jaip.2023.03.022. Epub 2023 Mar 29. J Allergy Clin Immunol Pract. 2023. PMID: 36997119 Review.
-
Intermittent or Sequential Topical Tacrolimus in Atopic Dermatitis: Systematic Review and Meta-Analysis.Cureus. 2023 Dec 16;15(12):e50640. doi: 10.7759/cureus.50640. eCollection 2023 Dec. Cureus. 2023. PMID: 38229798 Free PMC article. Review.
Cited by
-
Microbiome in atopic dermatitis.Clin Cosmet Investig Dermatol. 2017 Feb 22;10:51-56. doi: 10.2147/CCID.S130013. eCollection 2017. Clin Cosmet Investig Dermatol. 2017. PMID: 28260936 Free PMC article. Review.
-
Assessment of quality of life, treatment practices, and associated factors among children of atopic dermatitis patients at all Africa leprosy, TB and rehabilitation training center (A.L.E.R.T): a prospective observational study.BMC Pediatr. 2025 Mar 27;25(1):241. doi: 10.1186/s12887-025-05616-6. BMC Pediatr. 2025. PMID: 40148824 Free PMC article.
-
Staphylococcus aureus and the Cutaneous Microbiota Biofilms in the Pathogenesis of Atopic Dermatitis.Microorganisms. 2019 Aug 29;7(9):301. doi: 10.3390/microorganisms7090301. Microorganisms. 2019. PMID: 31470558 Free PMC article. Review.
References
-
- Sulzberger MB, Witten VH. The effect of topically applied compound F in selected dermatoses. J Invest Dermatol. 1952;19(2):101–102. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials